In a cohort of adults with rheumatoid arthritis, low adalimumab levels and ADAs at 3 months, not obtained at trough but during routine clinical visits, were significant predictors of no response after 1 year of treatment (25). The gene discussed is AGPS; the disease is rheumatoid arthritis.